The NIPT market  will reach USD 9,229.2 million, propelling at a 9.8% compound annual growth rate, by 2030. 

The growth in this industry is because of the surging occurrence of chromosomal abnormalities, particularly with the rising age of the mother, coupled with the growing necessity for early detection means.  

Precisely, the industry will be further boosted by the rising incidence of Down syndrome as well as the increasing acceptance of developed noninvasive tests. Also, the swift progressions in research & development for genetic ailments by research institutes will boost the implementation of NIPT.  

In the past few years, the consumables category, on the basis of product, was the largest contributor to the industry. This can be mainly because of the presence of a high number of companies offering consumables, counting reagents, disposables, and assay kits.  

Moreover, the largest contribution is also because of the enhancements in the assessments for NIPT as well as the high number of approvals to different assays.  

Furthermore, the instruments category is also witnessing remunerative growth. Moreover, NGS systems, under the instruments category, are utilized the most to identify fetal chromosomal irregularities. In addition, NGS is favored for the sequencing of whole genomes because it provides exceptional clinical efficiency. 

In the past few years, the cell-free DNA in maternal plasma tests category, on the basis of method, was the largest contributor to the NIPT market. The cell-free DNA technique is extensively employed owing to its usefulness in speculating the possibility of genetic irregularities.  

Furthermore, because of the exceptional accurateness of the results offered by cell-free DNA in maternal plasma tests, most people accept this technique. 

The trisomy category, based on application, has been a major contributor to the industry in recent years. This is because of the rising count of women becoming pregnant at a greater age, which significantly raises the possibility of chromosomal anomalies.

North America led the industry in recent years. This can be because of the robust healthcare infrastructure as well as the developments of technology in the diagnostics field.  

Moreover, the U.S. is leading the North American industry, and it is likely to propel at an 8% CAGR, mainly because of the robust financial backing. The rising occurrence of chromosomal anomalies in this nation has resulted in an increasing need for prenatal testing.  

APAC will advance at a significant rate, mainly because of the surging requirement to treat chromosomal anomalies in China and India. Moreover, this region is home to an enormous populace suffering from genetic ailments. 

With the surge in the necessity for early detection methods, the NIPT industry will continue to progress in the coming years. 

SOURCE: P&S Intelligence